TrialJournal of the American College of Cardiology2014

Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart disease.

Jacob A Udell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.